A Phase III, Open Label Study to Evaluate the Safety and

Project: Research project

Project Details

Description

A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN?? (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC).
StatusActive
Effective start/end date9/15/169/14/22

Funding

  • FKD THERAPIES OY

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.